Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

In computing diluted loss per share, no effect has been given to the common shares issuable upon conversion or exercise of the following dilutive securities as the Company’s net loss would make the effect anti-dilutive.

	June 30, 2015		December 31,
	(unaudited)		2014
Series A convertible preferred stock		-		625,895
Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest)		-		1,262,651
Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest)		-		537,233
Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest)		-		2,145,810
Common stock warrants		637,980		18,176
Employee stock options		1,156,090		752,372
Total common shares issuable		1,794,070		5,342,137

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table represents the fair value of the warrant liability measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3		Total
As of December 31, 2014
Non-current liabilities:
Warrant liability	$	-	$	-	$	303,102	$	303,102

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following are the changes in the level 3 warrant liability for the six months ended June 30, 2015:

Beginning balance at December 31, 2014	$	303,102
Settlement of warrant liability		(79,930)
Change in fair value		(223,172)
Ending balance at June 30, 2015	$	0